27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA's Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in support of approval of Innoviva Inc's (NASDAQ:INVA) sulbactam-durlobactam for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).
- The sulbactam-durlobactam marketing application was accepted and granted Priority Review by the FDA in November 2022, with a PDUFA target action date of May 29, 2023.
- Entasis Therapeutics, acquired by Innoviva last year, is developing the drug in partnership with Zai Lab Ltd (NASDAQ:ZLAB).
- Also Read: Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal.
- The Committee based its recommendation on the totality of scientific evidence, including results from the landmark Phase 3 trial.
- In the trial, sulbactam-durlobactam demonstrated statistical non-inferiority versus colistin for the primary endpoint of 28-day all-cause mortality and a significant difference in clinical cure rates.
- Sulbactam-durlobactam also exhibited a favorable safety profile with a statistically significant lower incidence of nephrotoxicity.
- If approved, the company will "look to explore commercial availability sometime later in the year," David Altarac, chief medical officer of Entasis Therapeutics, told Reuters ahead of the panel meeting.
- Price Action: INVA shares are down 1.13% at $13.07 during the premarket session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!